F-star Therapeutics, Inc. (FSTX)


+0.08 (+1.90%)
Symbol FSTX
Price $4.29
Beta 0.067
Volume Avg. 0.49M
Market Cap 94.302M
Shares () -
52 Week Range 2.07-6.93
1y Target Est -
DCF Unlevered FSTX DCF ->
DCF Levered FSTX LDCF ->
ROE -57.08% Strong Sell
ROA -53.45% Strong Sell
Operating Margin -
Debt / Equity 47.03% Neutral
P/E -
P/B 1.65 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest FSTX news

NASDAQ Capital Market

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.